Personal pdf file for

Dorota Kotowska, Rime B. El-Houri, Kamil Borkowski, Rasmus K. Petersen, Xavier C. Fretté, Gerhard Wolber, Kai Grevsen, Kathrine B. Christensen, Lars P. Christensen, Karsten Kristiansen

With compliments of Georg Thieme Verlag

www.thieme.de



Isomeric C₁₂-Alkamides from the Roots of *Echinacea purpurea* Improve Basal and Insulin-Dependent Glucose Uptake in 3T3-L1 Adipocytes

DOI 10.1055/s-0034-1383252 Planta Med 2014; 80: 1712–1720

For personal use only. No commercial use, no depositing in repositories.

Publisher and Copyright: © 2014 by Georg Thieme Verlag KG Rüdigerstraße 14 70469 Stuttgart ISSN 0032-0943

Reprint with the permission by the publisher only



Isomeric C₁₂-Alkamides from the Roots of Echinacea purpurea Improve Basal and Insulin-Dependent Glucose Uptake in 3T3-L1 Adipocytes

Authors

Dorota Kotowska^{1*}, Rime B. El-Houri^{2*}, Kamil Borkowski¹, Rasmus K. Petersen¹, Xavier C. Fretté², Gerhard Wolber³, Kai Grevsen⁴, Kathrine B. Christensen², Lars P. Christensen², Karsten Kristiansen¹

Affiliations

The affiliations are listed at the end of the article

Key words

- Echinacea purpurea
- Asteraceae
- alkamides
- adipocytes
- glucose uptake
- PPARy partial agonist

received	June 24, 2014
revised	August 23, 2014
accepted	October 12, 2014

Bibliography

DOI http://dx.doi.org/ 10.1055/s-0034-1383252 Published online November 5, 2014 Planta Med 2014; 80: 1712-1720 © Georg Thieme Verlag KG Stuttgart · New York · ISSN 0032-0943

Correspondence Prof. Dr. Lars P. Christensen

Department of Chemical Engineering Biotechnology and Environmental Technology University of Southern Denmark Campusvej 55 5230 Odense M Denmark Phone: + 45 65 50 73 61 Fax: +4565507354 lpc@kbm.sdu.dk

Abstract

Echinacea purpurea has been used in traditional medicine as a remedy for the treatment and prevention of upper respiratory tract infections and the common cold. Recent investigations have indicated that E. purpurea also has an effect on insulin resistance. A dichloromethane extract of E. purpurea roots was found to enhance glucose uptake in adipocytes and to activate peroxisome proliferator-activated receptor γ . The purpose of the present study was to identify the bioactive compounds responsible for the potential antidiabetic effect of the dichloromethane extract using a bioassay-guided fractionation approach. Basal and insulin-dependent glucose uptake in 3T3-L1 adipocytes were used to assess the bioactivity of extract, fractions and isolated metabolites. A peroxisome proliferator-activated receptor y transactivation assay was used to determine the peroxisome proliferator-activated receptor y activating properties of the extract, active fractions and isolated metabolites. Two novel isomeric dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides together with two known C₁₂-alkamides and α -linolenic acid were isolated from the active fractions. The isomeric C12-alkamides were found to activate peroxisome proliferator-activated receptor γ , to increase basal and insulin-dependent glucose uptake in adipocytes in a dose-dependent manner, and to exhibit characteristics of a peroxisome proliferator-activated receptor y partial agonist.

Abbreviations

aP2:	adipocyte protein 2		
C/EBPa:	CCAAT/enhancer-binding protein α		
CS:	calf serum		
DCM:	dichloromethane		
DI:	dexamethasone and insulin		
DMEM:	Dulbecco's modified Eagle's medium		
FCS:	fetal calf serum		
Glut:	glucose transporter		
GST:	glutathionine-S-transferase		
GU:	glucose uptake		
LBD:	ligand binding domain		
MDI:	1-methyl-3-isobutylxanthine,		
	dexamethasone and insulin		
PBS:	phosphate-buffered saline		
PPAR:	peroxisome proliferator-activated		
	receptor		
qPCR:	real-time quantitative polymerase		
	chain reaction		
Rosi:	rosiglitazone		
SCD1:	stearoyl-coenzyme A desaturase 1		
T2D:	type 2 diabetes		
TFA:	trifluoroacetic acid		
TR-FRET:	time-resolved fluorescence resonance		
	energy transfer		
TZD:	thiazolidinedione		

Supporting information available online at http://www.thieme-connect.de/products

Introduction

Echinacea purpurea (L.) Moench. (Asteraceae) is commonly used in traditional medicine for the treatment and prevention of upper respiratory tract infections and the common cold. Commercial medicinal preparations of *E. purpurea* have

been shown to possess immunomodulatory and anti-inflammatory effects which explain the traditional use of the plant [1,2]. Furthermore, we have previously shown that lipophilic extracts of

^{*} Dorota Kotowska and Rime B. El-Houri contributed equally to the work.




Fig. 1 Effects of dichloromethane extract of *Echinacea purpurea* roots and active fractions A and D on: **A** Glucose uptake in adipocytes at 100 μ g/mL with insulin concentrations of 0, 3, and 10 nM. **B** PPARy transactivation at 1, 10, and 100 μ g/mL. DMSO (vehicle) was set to 1 and the results normalized to this, while Rosi (1 μ M) was the positive control. In the PPARy transactivation assay, Rosi was 37-fold relative to DMSO. All values are expressed as mean ± SD of three independent experiments in triplicates; * p < 0.001 indicates significance relative to DMSO. (Color figure available online only.)

E. purpurea activate PPARy and enhance insulin-stimulated GU in adipocytes *in vitro* in a dose-dependent manner [3,4] and thus may have an effect on insulin resistance and T2D.

Adipose tissue plays a key role in energy homeostasis as a metabolic and endocrine organ. Adipocytes are targets for drugs reducing obesity or ameliorating obesity-associated metabolic disorders such as T2D [5]. TZDs have been used as insulin sensitizers in the management of T2D. TZDs regulate the expression of genes involved in insulin signaling and glucose and lipid metabolism in mature adipocytes but also promote adipocyte differentiation by acting as PPARy full agonists setting into motion gene cascades promoting differentiation and accumulation of triglycerides in adipocytes accentuating adiposity [6]. Furthermore, the potent TZDs cause undesirable side effects, including edema, fluid retention, weight gain, cardiac failure, and hepatotoxicity. Due to the observed hepatotoxicity, two TZD drugs were recently withdrawn from the market and the remaining one, pioglitazone, has been reassessed in light of increased risk of bladder cancer [7]. Limitations of the TZDs have driven research towards new types of drugs, which are able to increase insulin sensitivity acting as PPARy partial agonists, and therefore possibly ameliorate obesity-related insulin resistance without causing the side effects observed in relation to many, if not all, full PPARy agonists.

A number of natural plant-derived compounds have been shown to improve insulin sensitivity and may thus serve as starting point for discovery and design of novel drugs and herbal medicine to treat and prevent metabolic disorders with fewer side effects compared to synthetic drugs [8]. The bioactive metabolites considered responsible for the pharmacological activities of E. purpurea comprise polysaccharides, caffeic acid derivatives and alkamides [1,4,9–11]. From the florets of *E. purpurea*, a C₁₆-alkamide has been isolated that significantly activated PPARy and stimulated GU in adipocytes in vitro [4]. The roots of E. purpurea have a relative high content of alkamides [12-14], of which some are known for their immunomodulatory and anti-inflammatory effects [1,2]. However, very little is known about these bioactive compounds in relation to their effects on GU and PPARy. In the present study, it is shown that a crude DCM extract of E. purpurea roots was able to enhance GU in 3T3-L1 adipocytes and to activate PPARy. Hence, we decided to identify the metabolites responsible for the potential antidiabetic effect of this lipophilic extract using a bioassay-guided fractionation approach. Basal and insulin-dependent GU in adipocytes were used to assess the bioactivity of fractions and isolated compounds. In addition, we determined the PPARy activating properties of active fractions and

isolated metabolites in order to determine how their effect on GU in adipocytes correlated with their PPARy activating properties.

Results and Discussion

We have previously screened 133 plant extracts in different assays including PPARy transactivation, adipocyte differentiation, and insulin-dependent GU [3]. In this former investigation, the crude DCM root extract of E. purpurea was found to activate PPARy and to increase insulin-dependent GU, while it did not promote adipogenesis. The present study stays in agreement with these data (**•** Fig. 1; Fig. 1S, Supporting Information). The results revealed that basal GU in cells treated with the DCM extract was increased approximately 2-fold compared to control and was enhanced in the presence of 3 and 10 nM of insulin, suggesting that the extract increased insulin sensitivity in 3T3-L1 adipocytes (**• Fig. 1 A**). Furthermore, the DCM extract was shown to activate PPARy in transfected cell cultures in a dose-dependent manner (**C** Fig. 1B), acting as a weak PPARy agonist compared to the full agonist Rosi, and did not inhibit MDI-induced adipocyte differentiation or promote adipocyte differentiation of DI-treated 3T3-L1 preadipocytes (Fig. 1S).

A bioassay-guided approach was used to identify active metabolites from the crude DCM extract with interesting properties in relation to GU. Initial separation of the extract by flash chromatography resulted in nine fractions (A–I), of which fractions A and D were found to increase insulin-dependent GU in the presence of 3 nM and 10 nM insulin (**○** Fig. 1 A). The observed effect of the active fractions A and D on GU could be due to the presence of natural products with PPARy activity, and they were therefore tested for this activity. Fractions A and D were found to activate PPARy acting as weak agonists (**○** Fig. 1 B). However, the lack of correlation between insulin-dependent GU and PPARy activity (**○** Fig. 1) suggests that the effect on GU uptake, at least partially, may be due to compounds acting as partial agonists. In addition, fractions A and D did not promote adipogenesis using the DI protocol (Fig. 1S, Supporting Information).

HPLC-PDA-APCI-MS/MS analysis revealed that fraction A contained fatty acids with α -linolenic acid being a major constituent, while fraction D contained alkamides. α -Linolenic acid is a wellknown PPAR γ agonist [4,15] and has previously been shown to improve glucose tolerance, insulin sensitivity, dyslipidemia, hypertension, and ventricular stiffness in rats [16,17]; thus fraction A was not investigated further. Separation of fraction D by semipreparative HPLC yielded four alkamides (**• Fig. 2A**), of which




Fig. 2 A Chemical structures of alkamides (compounds 1–4) isolated from an active fraction (fraction D) of a dichloromethane root extract of *Echinacea purpurea*. Compounds 1 and 2 were isolated as an inseparable mixture (named compounds 1/2). B Predicted binding modes of compounds 1/2 shown as a 3D representation. C 2D representation of the chemical features of the interaction pattern derived from the docking pose for compound 1. The interaction pattern is the same for compound 2. Chemical features in the 2D representation are: red arrow = hydrogen-bond donor; blue line = hydrophobic contacts. (Color figure available online only.)

two are new isomeric C_{12} -alkamides (**1**, **2**). The known alkamides dodeca-2*E*,4*E*,8*Z*-trienoic acid isobutylamide (**3**) and dodeca-2*E*,4*E*-dienoic acid isobutylamide (**4**) have previously been isolated from the roots of *E. purpurea* [12, 14, 18].

Compounds 1 and 2 were obtained as an inseparable 1:1 mixture (compounds 1/2) that gave a quasi-molecular precursor ion at m/z 262 [M + H]⁺. The molecular formula C₁₇H₂₇NO (5 degrees of unsaturation) was assigned based on HR-ESI-MS data. The MS/ MS fragmentation pattern of the quasi-molecular precursor ion of compounds 1/2 showed characteristic product ions for 2methylbutylamides (**CFig. 3**) [13, 14, 19–21]. The presence of a 2-methylbutylamine moiety was confirmed by the ¹H NMR signals at δ 0.90 (d, J = 7 Hz, H₃-5'), 0.90 (t, J = 7 Hz, H₃-4'), 1.17 (m, H-3'b), 1.41 (m, H-3'a), 1.58 (m, H-2'), 3.16 (m, H-1'b), 3.28 (m, H-1'a), and 5.43 (brs, NH) [12], and was further substantiated by the ¹H–¹H COSY spectrum (**• Table 1**). The UV spectrum showed absorption maxima at 235 and 261 nm indicating a 2,4diene moiety and an additional diene chromophore in the structure of 1 and 2 [12,21]. The relative intensities of the fragments at *m*/*z* 149 (100%, base peak) and *m*/*z* 147 (24%) of the MS/MS fragmentation pattern were in agreement with compounds 1/2 being 2,4-diene alkamides [13, 14, 20]. The presence of four carbon-carbon double bonds in 1 and 2 was evident from the ¹H NMR showing signals from 2 × 8 olefinic protons (**• Table 1**). The low-field shift of the methine proton at C-3 (δ 7.18) confirmed that one of the double bonds was attached next to the amide moiety [12,22]. The positions of the other double bonds were determined from the ¹H–¹H COSY spectrum thus establishing the four double bonds in positions 2, 4, 8, and 10, respectively (**• Table 1**). The double bonds in positions 2 and 4 were assigned an *E* configuration on the basis of a coupling constant of 15 Hz, and the double bond in position 8 was assigned a Z configuration due to a coupling constant of 11 Hz [12]. Similarly, the double bond in position 10 was assigned as being *E* or *Z* (**• Table 1**). Hence, the chemical structure of compounds 1 and 2 was established as dodeca-2E,4E,8Z,10E-tetraenoic acid 2-methylbutylamide and dodeca-2E,4E,8Z,10Z-tetraenoic acid 2-methylbutylamide, respectively (**©** Fig. 2A).




Fig. 3 Proposed fragmentation pathway of the protonated molecular ion (MH⁺) of dodeca-2E,4E,8Z,10E-tetraenoic acid 2-methylbutylamide (1) as determined by MS/MS, including chemical structures of some of the most characteristic fragments. The base peak fragment at m/z149 (not shown) is probably formed when a double bond of the original 2,4-diene shifts to the 3-position, with a subsequent gain of two hydrogens [13, 14, 20]. The fragmentation pathway of the 2E,4E,8Z,10Z-isomer (2) is the same as illustrated above.

Compounds **3** and **4** showed a weak increase of basal GU and insulin-dependet GU at 3 nM insulin in mature 3T3-L1 cells at 30 μ M, whereas no increase of insulin-dependent GU was observed at 10, 30 and 100 nM insulin (**Fig. 2S**, Supporting Information) despite their ability to weakly activate PPAR γ , which is, for compound **4**, in accordance with previous investigations [4]. Dodeca-2*E*,4*E*,8*Z*,10*E*/*Z*-tetraenoic acid isobutylamides are among the major alkamides in *E. purpurea* but have previously been shown not to activate PPAR γ [4]. This may also explain why these alkamides were detected in the non-active fraction F according to the GU bioassay (data not shown). Compounds **1**/**2** at 30 μ M significantly increased basal GU 6.3-fold compared to the vehicle and 3-fold compared to Rosi (**O Fig. 4A**). A significant stimulation of insulin-dependent GU in the presence of 3, 10, 30 and 100 nM

5	Table 1 ¹ H NMR and ¹ H- ¹ H COSY
	spectral data (CDCl ₃ , 400 MHz) of
	dodeca-2E,4E,8Z,10E-tetraenoic
	acid 2-methylbutylamide (1) and
	dodeca-2E,4E,8Z,10Z-tetraenoic
	acid 2-methylbutylamide (2).

¹H⁻¹H COSY correlations

H-3

H-2, H-4

H-3, H-5

H-4, H₂-6

H-5, H₂-7

H₂-6, H-8

H₂-7, H-9

H-8, H-10

H-9, H-11

H-11

H₂-1′ H-2′, NH

H-2', NH

H-2', H₃-4'


H-2', H₃-4'

H₂-3'

H-2'

H2-1', H2-3', H3-5

H-10, H₃-12



н

2

3

5

6

8

9

10

11

12

NH

1'a

1'b

2'

3′a 3′b

4'

5'

Compound 1

5.76 d (15 Hz)

 δ^{1} H (ppm) (/ in Hz)

7.18 dd (15; 11 Hz)

6.17 dd (15; 11 Hz)

6.08 dt (15; 7 Hz)

5.97 dd (11: 11 Hz)

6.25 dd (15; 11 Hz)

5.69 dq (15; 7 Hz)

1.78 brd (7 Hz)

2.28 m

2.28 m

5.25 m

5.43 brs

3.28 m

3.16 m

1.58 m

1.41 m

1.17 m

0.90 t (7 Hz)

0.90 d (7 Hz)

Compound 2

5.76 d (15 Hz)

 δ^{1} H (ppm) (J in Hz)

7.18 dd (15; 11 Hz)

6.17 dd (15; 11 Hz)

6.30 dd (11: 11 Hz)

6.32 dd (11: 11 Hz)

5.55 dq (11; 7 Hz)

1.75 brd (7 Hz)

6.08 dt (15; 7 Hz)

2.28 m

2.28 m

5.36 m

5.43 brs

3.28 m

3.16 m

1.58 m

1.41 m

1.17 m

0.90 t (7 Hz)

0.90 d (7 Hz)

Fig. 4 Effect of compounds 1/2 on insulin-dependent glucose uptake: A At 30 μ M of compounds 1/2 with insulin concentrations of 0, 3, 10, 30 and 100 nM. B Dose-dependent effect of compounds 1/2 at 10 nM insulin. DMSO (vehicle) was set to 1 and the results normalized to this, while Rosi (1 μ M) was the positive control. All values are expressed as mean ± SD of three independent experiments in triplicates; * p < 0.001 indicates significance relative to DMSO. (Color figure available online only.)

insulin was also observed in cells treated with 30 µM of compounds 1/2 (OFig. 4A). Compounds 1/2 also dose-dependently increased GU in the presence of 10 nM insulin (O Fig. 4B). The effects of compounds 1/2 on GU resemble those of hexadeca-2E,9Z,12Z,14E-tetraenoic acid isobutylamide, previously isolated from the flowers of E. purpurea [4]. Similar to hexadeca-2E,9Z,12Z,14E-tetraenoic acid isobutylamide, compounds 1/2 increased transactivation of PPARy significantly at a concentration of 30 µM compared to vehicle but still weak relative to Rosi (OFig. 5A). Furthermore, compounds 1/2 and Rosi both competed with a fluorescent pan PPAR agonist in a ligand binding assay indicating a common binding site in the PPARy LBD (**•** Fig. 5B) [23]. These results indicate that compounds 1/2 may function as PPARy partial agonists. The docking mode and interactions of compounds 1/2 with the LBD (O Fig. 2B, C) support the assumption that compounds 1/2 are PPARy partial agonists. The PPARy LBD contains a large Y-shaped ligand binding cavity consisting of an entrance (arm III) that branches off into two binding pockets (arm I and II). Arm I is the only substantially polar cavity of the PPARy LBD, whereas arms II and III are mainly hydrophobic [24,25]. The predicted binding modes of compounds 1/2 with the

PPARy LBD included one hydrogen bond with Ser342 and several hydrophobic contacts with Ala292, Ile281, Ile296, Ile326, Ile341, Leu333, and Met348 from arms II and III of the LBD of PPARy (**• Fig. 2C**). These contacts are typical for PPARy partial agonists [24]. The fact that dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides do not seem to activate PPARy suggests that the hydrophobic contacts to Ile341 and Met348 are important for compounds 1/2 being PPARy partial agonists. In addition, no hydrogen bond interaction between 1/2 and residues Ser289, His323, His449, and/or Tyr473 from arm I of the LBD of PPARy was predicted, which are typical for PPARy full agonists. It has been a general notion that the binding mode of PPARy partial agonists affects the recruitment of co-activators differently from that of full agonists and decreases the transactivation activity of PPARy resulting in fewer side effects, but still maintains an insulin sensitizing effect [26]. In the present study, the weak activation of PPARy by compounds 1/2, combined with the results of the competitive PPARy binding assay and the docking mode of 1/2, suggests that these compounds are acting as PPARy partial agonists and that the 2-methylbutylamide moiety is important for their activity.




Fig. 5 Effect of compounds 1/2 on peroxisome proliferator-activated receptor y: A Transactivation of PPARv at a concentration of 30 µM. DMSO (vehicle) was set to 1 and the results normalized to this. Rosi (1 µM) was the positive control. All values are expressed as mean ± SD of three independent experiments in triplicates; p < 0.001 indicates significance relative to DMSO. B Effect of Rosi (0.001-3 uM) and compounds 1/2 (0.1, 0.3, 1, 3, 10, and 30 µM) in LanthaScreen[™] TR-FRET competitive PPARy binding assay in the agonist mode. Relative fluorescence units (RFU) are expressed as mean ± SD of three independent experiments in triplicates. An unrestrained sigmoidal (one-binding site) doseresponse curve was fitted to each data set by linear regression. (Color figure available online only.)

The alkamides are structurally related to natural endogenous and/or dietary PPAR γ ligands such as fatty acids [27, 28], prostanoids [28, 29], phospholipids [30], and polyacetylenes [31]. The PPAR γ activating properties of these ligands depend on the length of their aliphatic chain and functional groups such as carboxylate/carboxyl, α , β -unsaturated ketone, and/or hydroxyl, and thus on their interactions with the LBD. For example, the PPAR γ activating properties of some endogenous prostanoids and oxidized polyunsaturated fatty acids seem to be related to their ability to bind covalently to Cys285 of PPAR γ LBD through a Michael

addition reaction with an α , β -unsaturated ketone [32–34]. Polyacetylenes of the falcarindiol-type containing hydroxyl groups at one or two positions along their C₁₇-aliphatic chain were also shown to display PPAR γ partial agonism, which was confirmed by molecular docking studies suggesting a binding to the LBD in a manner similar to that observed for compounds **1**/**2** and other PPAR γ partial agonists [31]. However, the large cavity of the PPAR γ LBD, and thus the broad specificity of this receptor, makes the prediction of PPAR γ activity of ligands such as alkamides and other fatty acid derivatives difficult based on their chemical structure alone, in accordance with the results of the present study.

Increased expression of adipose cell differentiation markers is associated with insulin sensitivity [35], which may to some extent explain the insulin-dependent and basal GU data obtained in this study. The critical window for ligand-dependent induction of adipocyte differentiation of 3T3-L1 preadipocytes is days 0 to 4 after induction of differentiation [36]. To investigate possible mechanisms by which compounds 1/2 might affect the early stages of adipocyte differentiation, we examined the expression of genes involved in adipogenesis (PPAR γ , C/EBP α , and aP2, also known as fatty acid binding protein 4), glucose transport (Glut1 and Glut4), lipogenesis (SCD1), and adipokine (adiponectin) (• Table 2) in mature 3T3-L1 cells treated with 30 µM of compounds 1/2 during the first 4 days of differentiation (days 0-4) using the DI and MDI protocols. Compounds 1/2 increased the expression of PPARy, aP2, C/EBP α , adiponectin and Glut1 in the MDI differentiation medium (O Fig. 6A). However, when the cAMP elevating agent 1-methyl-3-isobutylxanthine was omitted in the cocktail (DI differentiation medium), the expression of several genes was significantly downregulated (**○** Fig. 6B). These results suggest that compounds 1/2 require elevated cAMP levels to increase the expression of key markers of adipogenesis. SCD1 expression was significantly downregulated by treatment with $30\,\mu\text{M}$ of compounds 1/2 in both the MDI and DI treatment (• Fig. 6). SCD1 is involved in lipogenesis, and therefore a downregulation of this gene may result in decreased lipogenesis and a small size of lipid droplets [37].

PPARγ agonists are known to increase glucose transport and insulin sensitivity by regulating expression of several genes involved in glucose metabolism [38]. GU in adipocytes is correlated with the number of glucose transporters [39]. Glut1 is expressed in both preadipocytes and mature adipocytes and is responsible for basal glucose transport. By contrast, Glut4 is expressed only in mature adipocytes and supports insulin-dependent GU [40, 41]. In this study, compounds 1/2 increased gene expression of Glut1,

Genes	5'-prime (forward)	3'-prime (reverse)	Table 2 Primer sequences used
Adipogenesis process related			for analysis of gene expression.
C/EBPa	CAAGAACAGCAACGAGTACCG	GTCACTGGTCAACTCCAGCAC	
aP2	CTGGGCGTGGAATTCGAT	GCTCTTCACCTTCCTGTCGTCT	
PPARγ	ACAGCAAATCTCTGTTTTATGC	TGCTGGAGAAATCAACTGTGG	
Adipokine gene			
Adiponectin	GATGGCAGAGATGGCACTCC	CTTGCCAGTGCTGCCGTCAT	
Glucose transporter			
Glut1	TGTATCCTGTTGCCCTTCTGC	CGACCCTCTTCTTTCATCTCCT	
Glut4	CAGAAGGTGATTGAACAGAGC	CCCTGATGTTAGCCCTGAG	
Lipogenesis related			
SCD1	ACACCTGCCTCTTCGGGATT	TGATGGCCAGAGCGCTG	
Reference gene			
TATA box-binding protein	ACCCTTCACCAATGACTCCTATG	ATGATGACTGCAGCAAATCGC	




Fig. 6 Effect of compounds 1/2 in a concentration of 30 µM on gene expression of peroxisome proliferator-activated receptor γ , adipocyte protein 2, CCAAT/enhancer-binding protein α , stearoyl-coenzyme A desaturase 1, adiponectin, glucose transporters 1 and 4 in differentiating 3T3-L1 cells in the: **A** MDI protocol. **B** DI protocol. DMSO (vehicle) was set to 1 and the results normalized to this, while Rosi (1 µM) was the positive control. All values are expressed as mean ± SD of three independent experiments in triplicates; * p < 0.001 indicates significance relative to DMSO. (Color figure available online only.)

but not Glut4, when the MDI differentiation medium was used (**o Fig. 6A**), whereas compounds **1/2** decreased the expression of the Glut4 transporter and did not significantly affect the expression of the Glut1 transporter in the DI differentiation medium (**o Fig. 6B**). This could indicate that compounds **1/2** in the context of MDI-induced differentiation enhanced basal GU by upregulation of Glut1 gene expression, whereas the observed insulin-dependent GU requiring Glut4 was unrelated to an increased expression of this transporter.

Adiponectin also plays an important role in mediating GU in adipocytes and was significantly upregulated by addition of compounds **1/2** in the MDI protocol (**• Fig. 6A**); hence, this suggests that the adipocytes might be insulin sensitive [42]. This finding fits with the stimulatory effects seen for the insulin-stimulated GU in adipocytes shown in **• Fig. 4**.

We have demonstrated that a lipophilic extract of the roots of *E. purpurea* had a significant effect on basal and insulin-dependent GU and was able to activate PPAR γ in transfected cell cultures. The bioassay-guided fractionation approach led to the isolation of an inseparable mixture of two new C₁₂-isomeric alkamides (compounds 1/2) that significantly enhanced basal and insulin-dependent GU in adipocytes and exhibited the characteristics of PPAR γ partial agonists.

Materials and Methods

Plant material

Plants of *Echinacea purpurea* (L.) Moench were propagated from seeds purchased from Rieger Hoffmann GmbH. The plantlets were raised in a greenhouse and transplanted in a sandy loam soil (Aarslev, Denmark; coordinates: 55.3° N, 10.5° E) in early June 2007. The roots were harvested in August 2010, washed and air-dried and stored at -25° C until use. *E. purpurea* plants were authenticated by one of the authors (Dr. Kai Grevsen), and a voucher specimen (EP2010) is deposited at the Department of Food Science, Aarhus University, Denmark.

Apparatus, materials, chemicals, and reagents

Semi-preparative HPLC was performed on a Dionex UltiMate 3000 binary semipreparative LC system (Thermo Scientific), equipped with a DAD (DAD-3000 RS) and a Foxy Jr. fraction collector (Teledyne ISCO Inc.). Separations were performed on a Develosil ODS-HG-5 RP-C18 column (5 µm; 250 × 20 mm i.d., Nomura Chemical Co.). UV and MS data were collected from an HPLC-PDA-MS/MS system, LTQ XL (Linear Quadrupole 2D Ion Trap, Thermo Scientific) mass spectrometer attached to a PDA detector. HR-ESI-MS was recorded on a 10205 micrOTOF-Q II focus high resolution mass spectrometer (Bruker Daltonics). NMR spectra were recorded on a Bruker 400 MHz spectrometer. Flash chromatography was performed in silica gel 60, particle size 0.063–0.2 mm, Merck and TLC in silica gel 60 aluminium sheets; 0.2 mm, 20 × 20 cm, Merck. MeCN, EtOAc, DCM, *n*-hexane, isopropanol, TFA, DMSO, dexamethasone, 1-methyl-3-isobutylxanthine, insulin, Oil Red O, and Rosi (HPLC purity \geq 98%) were purchased from Sigma-Aldrich; DMEM, FCS, CS, PBS, penicillin/ streptomycin, and TRIzol reagent from Invitrogen.

Plant extraction and isolation

Fresh *E. purpurea* roots (3 kg) were homogenized and extracted twice with DCM (10 L) for 24 h in the dark at 5 °C with periodical shaking. The extracts were combined, filtered, and dried under vacuum (30 °C) to give 9.3 g crude DCM extract (yield (w/w): 0.31%).

Initial separation of the DCM extract was done on a flash column (100 mm i.d., 300 g silica gel) conditioned with *n*-hexane. The DCM extract (8 g) was re-dissolved in DCM (20 mL), applied to the column and eluted using the following solvent gradient: 100% *n*-hexane (600 mL), 10–90% EtOAc in *n*-hexane in 10% steps (600 mL each), and 100% MeCN (1000 mL). Seventy fractions (100 mL each) were collected and combined into nine fractions (A–I) based on TLC: A (1.6 g), B (0.3 g), C (0.1 g), D (0.2 g), E (0.1 g), F (0.4 g), G (0.2 g), H (0.5 g), and I (2.9 g). TLC plates were developed using n-hexane-EtOAc (60:40) as eluent and were inspected by UV light followed by visualization with vanillin reagent. Testing of the fractions A-I in the GU bioassay revealed two active fractions, A and D (**• Fig. 1A**), which were further tested in the PPARy transactivation bioassay (**© Fig. 1 B**). Non-active fractions according to the GU bioassay (fraction B, C, E–I, data not shown) were not tested for PPARy activity.

The active fractions A and D were analyzed by HPLC-PDA-APCI-MS/MS according to the method described by Thomsen et al. [14]. Fraction A was found to contain fatty acids with α -lino-lenic acid as a major constituent. Fraction D contained alkamides and was re-dissolved at a concentration of 10 mg/mL in MeCN and separated by semi-preparative HPLC. Mobile phase: (A) water

containing 500 ppm TFA and (B) 100% MeCN containing 500 ppm TFA. Solvent gradient: 0 min, 25% B; 55 min, 100% B; 70 min, 100% B; 85 min, 25% B; column temperature 25°C; flow rate was 5 mL/min; injection volume was 2 mL; detection wavelengths were λ = 210, 254, and 280 nm. Separation of fraction D resulted in the isolation of dodeca-2E,4E,8Z,10E-tetraenoic acid 2-methylbutylamide (1) and dodeca-2E,4E,8Z,10Z-tetraenoic acid 2-methylbutylamide (2) as an 1:1 inseparable mixture (5.9 mg, HPLC purity \ge 96%; t_R = 36.9 min) named compounds 1/ 2, and the known metabolites dodeca-2E,4E,8Z-trienoic acid isobutylamide (3; 22.3 mg, HPLC purity \geq 96%; t_R = 38.4 min) and dodeca-2E,4E-dienoic acid isobutylamide (4; 17.5 mg, HPLC purity \geq 98%; t_R = 44.7 min). Compounds 1/2 were obtained as colourless oil; UV λ_{max} (nm): 235, 261. ¹H NMR (CDCl₃, 400 MHz), see **Table 1** and Supporting Information. HPLC-MS/MS (APCI; positive mode): m/z 262 [M + H]⁺ (quasi-molecular precursor ion) gave the following product ions (intensities in % relative to base peak in parenthesis): *m/z* 234 (4) [M + H – C₂H₄]⁺, 206 (3) $[M + H - C_4 H_8]^+$, 192 (6) $[M + H - C_5 H_{10}]^+$, 175 (28) $[M + H - H_8]^+$ C₅H₁₃N]⁺, 149 (100), 147 (24) [M + H - C₆H₁₃NO]⁺, 133 (13), 121 (13) [M + H - C₈H₁₅NO]⁺, 107 (18), 93 (15), 91 (6) [see also Supporting Information]. HR-ESI-MS m/z 262.2176 [M(C₁₇H₂₇NO) + H]⁺ (calcd. 262.2171) [Supporting Information]. The structures of compounds 3 and 4 were established based on comparison of NMR and MS data with literature reports [12, 14, 18].

Adipocyte cell cultures

3T3-L1 preadipocytes were cultured in DMEM with 10% CS supplemented with 1% penicillin/streptomycin at 37°C in humidified 95% air and 5% CO₂. At day two post-confluence (designated day 0), the cells were induced to differentiate with 500 µM 1methyl-3-isobutylxanthine, 1µM dexamethasone, and 167 nM insulin (MDI protocol), or with 1µM dexamethasone and 167 nM insulin (DI protocol). For both protocols, the medium was replaced at day 2 with DMEM supplemented with 10% FCS, 1% penicillin/streptomycin, and 167 nM insulin and thereafter every second day with DMEM supplemented with 10% FCS and 1% penicillin/streptomycin. Extract, fractions, and pure compounds were dissolved in 0.1% (v/v) DMSO and thereafter added to the medium to a final concentration as indicated. Vehicle cells were treated with 0.1% (v/v) DMSO equal to the DMSO concentration in the medium. Mature adipocytes were treated with the compounds from days 0-8 or days 0-4 as described.

Glucose uptake in adipocytes

Mature 3T3-L1 cells were seeded in 96-well plates and differentiated according to the MDI protocol till day 8. At day 8, the cells were fed with medium supplemented with DMSO, Rosi (1 μ M), and crude extract, fractions, or pure compounds. GU bioassay was performed 48 h later according to the method described by Christensen et al. [4]. GU was determined in eight parallel wells at each insulin concentration (**• Fig. 1A** and **Fig. 4**; **Fig. 2S**, Supporting Information).

Peroxisome proliferator-activated

receptor y transactivation bioassay

PPARy transactivation of vehicle [0.1% (v/v) DMSO], positive control (1 µM Rosi), crude extract, fractions, or pure compounds dissolved in DMSO (**• Fig. 5**) was performed on a mouse embryonic fibroblast cell line trypsinized at 70% confluence as described previously [4].

Competitive peroxisome proliferator-activated receptor y binding assay

Competitive binding was performed using TR-FRET (Lantha-Screen, Invitrogen) on Wallac EnVision (PerkinElmer). A terbium-labeled anti-GST antibody was used to label purified GST-tagged human PPAR γ LBD. Energy transfer from terbium to the tracer, a fluorescent pan PPAR agonist, enabled read-out of each test compound's ability to displace the tracer. Relative fluorescence values from dose-response curves for compounds 1/2 and Rosi (positive control) were analysed using GraphPad Prism software (**• Fig. 5**). An unrestrained sigmoidal (one-binding site) dose-response curve was fitted to each data set by linear regression.

Oil Red O staining

Mature 3T3-L1 cells were differentiated according to DI or MDI protocol and treated every second day with the designated medium and DMSO, Rosi (1 μ M), crude extract, fractions, or pure compounds until day 8. At day 10, cells were washed in PBS, fixed with 4% paraformaldehyde for 1 h and washed with double-distilled water. Cells were incubated with Oil Red O solution (8.57 mM Oil Red O in isopropanol) mixed 3:2 with water for 30 min and washed twice in water.

Molecular docking studies

Docking studies were performed using GOLD version 5.1 [43] and default parameters (GoldScore, 100% search efficiency). Protein Data Bank entry 2Q5S (human PPAR γ) was selected as protein template. The active site was determined by selecting all residues within a radius of 6 Å of the co-crystalized ligand for 2Q5S. Docking was performed with a hydrogen bond to Ser342 set to constraint since this interaction has been reported to be essential for binding of PPAR γ partial agonists [23]. After docking, all compounds were minimized using LigandScout's general purpose MMFF94 implementation [44]. The best docking poses for the ligands were selected by developing a 3D pharmacophore with LigandScout [45–47].

Real-time quantitative polymerase chain reaction

Total RNA was isolated on day 10 from maturing (days 0–4) 3T3-L1 adipocytes using TRIzol reagent. 500 ng of RNA were reverse transcribed with RevertAid (Fermentas) according to manufacturer's instructions. qPCR analysis was performed using the Mx3000P qPCR system (Agilent Technologies) and SYBRGreen JumpStart Taq ReadyMix (Sigma-Aldrich). Primers were purchased from Tag Copenhagen A/S. Data was analyzed using the $\Delta\Delta$ Ct method, and gene expression was normalized to TATA box binding protein (reference gene). Primer sequences used for analysis of gene expression are shown in **• Table 2**.

Statistical analysis

All data were analyzed by SAS statistical programming software (version 9.2; SAS Institute Inc.) and OriginPro software (Origin-Pro 8.0, OriginLab Corporation). Data were expressed as the mean \pm standard deviation (SD) of three independent experiments in triplicates. The identification of significances between different groups was carried out with Student's *t*-test. A p value < 0.05 was considered statistically significant.

Supporting information

Adipocyte differentiation of DI protocol-treated 3T3-L1 preadipocytes with DMSO, 100 µg/mL DCM extract, fraction A, fraction D, 30 µM compounds **1/2**, and 1 µM Rosi, respectively (**Fig. 1S**), the effect of compounds **3** and **4** at a 30 µM concentration on insulin-dependent GU (**Fig. 2S**), and the HR-ESI-MS, MS/MS, ¹H NMR and ¹H–¹H COSY spectra of compounds **1/2** are available as Supporting Information.

Acknowledgements

▼

This research was supported by the Danish Council for Strategic Research (Project No. 09–063086).

Conflict of Interest

▼

The authors declare no conflict of interest.

Affiliations

- ¹ Department of Biology, University of Copenhagen, Copenhagen, Denmark ² Department of Chemical Engineering, Biotechnology and Environmental
- Technology, University of Southern Denmark, Odense, Denmark ³ Computer-Aided Drug Design, Institute of Pharmacy, Medicinal and Pharma-
- central computer Anded Drug Design, institute of Pharmacy, Medicina and Pharmaceutical Chemistry, Freie Universität Berlin, Berlin, Germany
- ⁴ Department of Food Science, Aarhus University, Aarslev, Denmark

References

- 1 Barnes J, Anderson L, Gibbons S, Phillipson J. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2005; 57: 929–954
- 2 Woelkart K, Bauer R. The role of alkamides as an active principle of *Echinacea*. Planta Med 2007; 73: 615–623
- 3 Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, Schrader E, Rimbach G, Wein S, Wolfram S, Kristiansen K, Christensen LP. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. Phytother Res 2009; 23: 1316–1325
- 4 Christensen KB, Petersen RK, Petersen S, Kristiansen K, Christensen LP. Activation of PPARγ by metabolites from the flowers of purple coneflower (Echinacea purpurea). J Nat Prod 2009; 72: 933–937
- 5 *Nawrocki AR, Scherer PE.* Keynote review: the adipocyte as a drug discovery target. Drug Discov Today 2005; 10: 1219–1230
- 6 Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000; 16: 145–171
- 7 Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012; 23: 205–215
- 8 Yeh GY, Eisenberg DM, Kaptchnuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2013; 26: 1277–1294
- 9 *Starvaggi Cucuzza L, Motta M, Accornero P, Baratta M.* Effect of *Echinacea augustifolia* extract on cell viability and differentiation in mammary epithelial cells. Phytomed 2008; 15: 555–562
- 10 Spelman K, Liams-Hauser K, Cech NB, Taylor EW, Smirnoff N, Wenner CA. Role of PPARy in IL-2 inhibition in T cells by Echinacea-derived undeca-2E-ene-8, 10-diynoic acid isobutylamide. Int Immunopharmacol 2009; 9: 1260–1264
- 11 Goey AKL, Rosing H, Meijerman I, Sparidans RW, Schellens JHM, Beijnen JH. The bioanalysis of the major *Echinacea purpurea* constituents dodeca-2*E*,4*E*,8*Z*,10*E*/*Z*-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. J Chromatogr B 2012; 902: 151–156
- 12 Bauer R, Remiger P, Wagner H. Alkamides from the roots of Echinacea purpurea. Phytochem 1988; 27: 2339–2342
- 13 Spelman K, Wetschler MH, Cech NB. Comparison of alkylamide yield in ethanolic extracts prepared from fresh versus dry Echinacea purpurea utilizing HPLC-ESI-MS. J Pharm Biomed Anal 2009; 49: 1141–1149

- 14 Thomsen MO, Fretté XC, Christensen KB, Christensen LP, Grevsen K. Seasonal variations in the concentrations of lipophilic compounds and phenolic acids in the roots of *Echinacea purpurea* and *Echinacea pallida*. J Agric Food Chem 2012; 60: 12131–12141
- 15 Takahara Y, Kobayashi T, Takemoto K, Adachi T, Osaki K, Kawahara K, Tsujimoto G. Pharmacogenomics of cardiovascular pharmacology: development of an informatics system for analysis of DNA microarray data with focus on lipid metabolism. J Pharmacol Sci 2008; 107: 1–7
- 16 *Ghafoorunissa, Ibrahim A, Natarajan S.* Substituting dietary linoleic acid with α -linolenic acid improves insulin sensitivity in sucrose fed rats. Biochim Biophys Acta 2005; 21: 67–75
- 17 *Poudyal H, Panchal SK, Ward LC, Brown L*. Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. J Nutr Biochem 2013; 24: 1041–1052
- 18 Bauer R, Remiger P. TLC and HPLC analysis of alkamides in Echinacea drugs. Planta Med 1989; 55: 367–371
- 19 Cech NB, Eleazer MS, Shoffner LT, Crosswhite MR, Davis AC, Mortenson AM. High performance liquid chromatography/electrospray ionization mass spectrometry for simultaneous analysis of alkamides and caffeic acid derivatives from Echinacea purpurea extracts. J Chromatogr A 2006; 1103: 219–228
- 20 Mudge E, Loes-Lutz D, Brown P, Scheiber A. Analysis of alkylamides in Echinacea purpurea materials and dietary supplements by ultrafast liquid chromatography with diode array and mass spectrometric detection. J Agric Food Chem 2011; 59: 8086–8094
- 21 Pellati F, Epifano F, Contaldo N, Orlandini G, Cavicchi L, Genovese S, Bertelli D, Bevenuti S, Curini M, Bertaccini A, Bellardi MG. Chromatographic methods for metabolite profiling of virus- and phytoplasma-infected plants of Echinacea purpurea. J Agric Food Chem 2011; 59: 10425– 10434
- 22 Nakatani N, Nagashima M. Pungent alkamides from Spilanthes acmella L. var. oleracae Clarke. Biosci Biotechnol Biochem 1992; 56: 759–762
- 23 Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP, Baumgartner L, Fakhrudin N, Ladurner A, Malainer C, Vuorinen A, Noha SM, Schwaiger S, Rollinger JM, Schuster D, Stuppner H, Dirsch VM, Heiss EH. Honokiol: A nonadipogenic PPARY agonist from nature. Biochim Biophys Acta 2013; 1830: 4813–4819
- 24 Guasch L, Sala E, Valls C, Blay M, Mulero M, Arola L, Pujadas G, Garcia-Vallvé S. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des 2011; 25: 717–728
- 25 Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007; 1771: 915–925
- 26 Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE. Distinct properties and advantages of a novel peroxisome proliferatoractivated protein γ selective modulator. Mol Endocrinol 2003; 17: 662–676
- 27 *Thoennes SR, Tate PL, Price TM, Kilgore MW.* Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol Cell Endocrinol 2000; 160: 67–73
- 28 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–688
- 29 *Dussault I, Forman BM.* Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. Prostaglandins Other Lipid Mediat 2000; 62: 1–13
- 30 Hammond VJ, Morgan AH, Lauder S, Thomas CP, Brown S, Freeman BA, Lloyd CM, Davies J, Bush A, Levonen AL, Kansanen E, Villacorta L, Chen YE, Porter N, Garcia-Diaz YM, Schopfer FJ, O'Donnell VB. Novel ketophospholipids are generated by monocytes and macrophages, detected in cystic fibrosis, and activate peroxisome proliferator-activated receptor-γ. J Biol Chem 2012; 287: 41651–41666
- 31 Atanasov AG, Blunder M, Fakhrudin N, Liu X, Noha SM, Malainer C, Kramer MP, Cocic A, Kunert O, Schinkovitz A, Heiss EH, Schuster D, Dirsch VM, Bauer R. Polyacetylenes from Notopterygium incisum – new selective partial agonists of peroxisome proliferator-activated receptorgamma. PLoS ONE 2013; 8: e61755
- 32 Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, Kamiya N, Jingami H, Morikawa K. Structural insight into PPARγ activation through covalent modification with endogenous fatty acids. J Mol Biol 2009; 385: 188–199

- 33 Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JWR. Structural basis for the activation of PPARy by oxidized fatty acids. Nat Struct Mol Biol 2008; 15: 924–931
- 34 Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H. α,β-Unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J Biol Chem 2005; 280: 14145–14153
- 35 McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, Reaven GM, Cushman SW. Enhanced proportion of small adipose cells in insulin-resistant vs. insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 2007; 50: 1707–1715
- 36 Hallenborg P, Jorgensen C, Petersen RK, Feddersen S, Araujo P, Markt P, Langer T, Furstenberger G, Krieg P, Koppen A, Kalkhoven E, Madsen L, Kristiansen K. Epidermis-type lipoxygenase 3 regulates adipocyte differentiation and peroxisome proliferator-activated receptor gamma activity. Mol Cell Biol 2010; 16: 4077–4091
- 37 *Spiegelman BM.* PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–514
- 38 Ribon V, Johnson JH, Camp HS, Saltiel AR. Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor γ activation stimulates expression of CAP gene. Proc Natl Acad Sci USA 1998; 95: 14751–14756
- 39 Wood IS, Trayhurn P. Glucose transporter (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003; 89: 3–9

- 40 Gregoire FM, Johnson PR, Greenwood MR. Comparison of the adipoconversion of preadipocytes derived from lean and obese Zucker rats in serum-free cultures. Int J Obes Relat Metab Disord 1995; 19: 664–670
- 41 Shang W, Yang Y, Jiang B, Jin H, Zhou L, Liu S, Chen M. Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhacing PPARγ2 and C/EBPα gene expression. Life Sci 2007; 80: 618–625
- 42 Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941–946
- 43 *Jones G, Willett P, Glen RC*. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995; 245: 43–53
- 44 *Halgren TA.* Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996; 17: 490–519
- 45 Seidel T, Ibis G, Bendix F, Wolber G. Strategies for 3D pharmacophorebased virtual screening. Drug Discov Today Technol 2010; 7: 221–228
- 46 Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic molecules using 3D pharmacophores. J Comput Aided Mol Des 2006; 20: 773–788
- 47 Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inform Model 2005; 45: 160–169